| __timestamp | BioCryst Pharmaceuticals, Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 5699000000 |
| Thursday, January 1, 2015 | 13047000 | 5001000000 |
| Friday, January 1, 2016 | 11253000 | 5002000000 |
| Sunday, January 1, 2017 | 13933000 | 4849000000 |
| Monday, January 1, 2018 | 29514000 | 4551000000 |
| Tuesday, January 1, 2019 | 37121000 | 4871000000 |
| Wednesday, January 1, 2020 | 67929000 | 7661000000 |
| Friday, January 1, 2021 | 118818000 | 7690000000 |
| Saturday, January 1, 2022 | 159371000 | 7814000000 |
| Sunday, January 1, 2023 | 213894000 | 7772000000 |
| Monday, January 1, 2024 | 8414000000 |
Unveiling the hidden dimensions of data
In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Bristol-Myers Squibb Company and BioCryst Pharmaceuticals, Inc. offer a fascinating comparison in this regard. Over the past decade, Bristol-Myers Squibb has consistently maintained higher SG&A expenses, averaging around $6 billion annually. In contrast, BioCryst Pharmaceuticals, with a more modest scale, has seen its SG&A costs grow from approximately $7 million in 2014 to over $200 million in 2023, marking a significant increase.
Despite the disparity in absolute numbers, the growth rate of BioCryst's SG&A expenses is noteworthy, reflecting its expansion efforts. Meanwhile, Bristol-Myers Squibb's expenses have remained relatively stable, indicating efficient cost management at a larger scale. This comparison highlights the different strategies employed by large and small pharmaceutical companies in managing operational costs.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Genmab A/S vs BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?